GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Cash Flow from Others

Lirum Therapeutics (Lirum Therapeutics) Cash Flow from Others : $-0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Cash Flow from Others?

Lirum Therapeutics's cash flow from others for the three months ended in Dec. 2023 was $0.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00 Mil.


Lirum Therapeutics Cash Flow from Others Historical Data

The historical data trend for Lirum Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Cash Flow from Others Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Others
- - -

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Cash Flow from Others - - - - -

Lirum Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Lirum Therapeutics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines